MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: BioMedReports.com
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Updated Calendar Report on Twelve Extreme Trades with Pending FDA Decisions - Biomedical news portal profiles 12 companies with FDA decisions pending - BioMedReports.com
Updated Calendar Report on Twelve Extreme Trades with Pending FDA Decisions

 

NewswireToday - /newswire/ - Pasadena, CA, United States, 2009/05/20 - Biomedical news portal profiles 12 companies with FDA decisions pending - BioMedReports.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Consulting / Market Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Today, in a new special report, BioMedReports.com- the news portal covering the biomedical news and financial sector- has researched and released the details of 12 extreme FDA trades for 11 companies with market caps below $200M- all of which have pending new drug product decisions or other meetings/milestones scheduled with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced.

A high risk/reward trading approach to consider for speculative traders is covered in the report which features trades for:

• Hemispherx Biopharma (AMEX: HEB): Ampligen (Poly I: Poly C12U) NDA is an experimental treatment for chronic fatigue syndrome (which has no FDA-approved treatments) and the drug has an Orphan Drug Status with a PDUFA decision date of 5/25/09 (please note this is Memorial Day so the markets will be closed for a long weekend and re-open on Tuesday 5/26).

• Advanced Life Sciences (OTC: ADLS): ADLS has a pending NDA for cethromycin as a once-daily antibiotic for the treatment of adults with mild to moderate community acquired pneumonia (CAP) with a PDUFA decision date of 7/31/09. Also, the Anti-Infective Drugs Advisory Committee of the FDA is tentatively scheduled to meet on 6/2/09 to discuss the NDA for cethromycin and provide a recommendation for the final FDA approval decision.

• Spectrum Pharma (NASDAQ: SPPI): SPPI is a dual extreme trade with two pending decisions at the FDA. Zevalin sBLA (priority review) to expand the approved label to include consolidation therapy for follicular B-cell non-Hodgkin's lymphoma if a first-line treatment response is achieved with an expected PDUFA decision date of 7/2/09.

• Labopharm (NASDAQ: DDSS): A decision date of 7/18/09 is looming for the Company's rapid-onset formulation of trazodone (DDS-04A) for the treatment of depression through the 505(b)(2) regulatory pathway for new formulations drugs that are already on the market.

• Transcept Pharma (NASDAQ: TSPT): An expected PDUFA decision date of 7/30/09 is pending for Intermezzo (zolpidem sublingual lozenge) NDA for use as-needed to treat insomnia from middle of the night awakenings.

The full special report covering more details and profiles for all 11 companies can be found online.

About BioMedReports.com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars.

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Consulting / Market Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: BioMedReports.com

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Consulting / Market Research articles,
CATCH Visitors via Your Competitors Announcements!


Updated Calendar Report on Twelve Extreme Trades with Pending FDA Decisions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: M. Garza - BioMedReports.com 
323-472-4480 garza[.]biomedreports.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BioMedReports.com securities in any jurisdiction including any other companies listed or named in this release.

Consulting / Market Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BioMedReports.com / Company Profile


Read Consulting / Market Research Most Recent Related Newswires:

Kantar Recognised with 5x Gold and 3x Silver Awards At AMEC Grand Prix 2020
Kantar and Comscore Partnership with Auditel Italy Extended Until End of 2023
Kantar Launches an Online Oncology Platform to Support Physicians During the COVID-19 Pandemic
Frost & Sullivan and Integrated Intelligence Services (IIS Holding) Partner to Support Qatar’s Growth as an Innovation Hub
Kantar Acquires Mavens of London to Expand Digital Consultancy Offering
Kantar Announce Strategic Steps to Scale Client Impact in Australia
Global Augmented Analytics Market Forecast 2019-2027 Reports Inkwood Research
The Global FRP Pipe Market is Growing At 4.48% CAGR through 2027 Finds Inkwood Research
Compensation Consulting Responds to Global Trends with Data-Driven and Innovative Strategies
Aricent to Become Altran
Macromill, Inc. Acquires Southeast Asian Marketing Research Firm, W&S Holdings Co., Ltd
Kantar Moves To Single Brand
Kantar Marketplace Goes Live, Delivering Smart, On-demand Insights Globally
Ventana Research Names Infor Birst An Overall Leader in its 2019 Mobile Analytics and Business Intelligence Value Index
Kantar Joins Board of Movin’ On LAB to Advance Sustainable Mobility

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)